PET/MRI evaluation of hepatobiliary tumors.

Positron-emission tomography magnetic resonance imaging (PET/MRI) has emerged as a powerful hybrid molecular imaging technique in clinical practice, overcoming initial technical challenges to provide comprehensive anatomic and metabolic information. This advanced modality combines the superior soft tissue contrast of MRI with the metabolic insights of PET, offering advantages in hepatobiliary imaging, including improved detection of small liver metastases and reduced radiation exposure. The evolution of PET/MRI technology has been marked by significant advancements, such as the development of MRI-compatible PET detectors and sophisticated motion compensation techniques.

Comparison of BMIPP-SPECT/CT to FDG-PET/CT for Imaging Brown or Browning Fat in a Preclinical Model.

Obesity is a leading cause of preventable death and morbidity. To elucidate the mechanisms connecting metabolically active brown adipose tissue (BAT) and metabolic health may provide insights into methods of treatment for obesity-related conditions. F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is traditionally used to image human BAT activity.

Androgen Deprivation Therapy Differentially Impacts Bone and Muscle in the Short Term in Physically Active Men With Prostate Cancer.

Androgen deprivation therapy (ADT) is a cornerstone of advanced prostate cancer (PCa) therapy. Its use is associated with a loss of bone mineral density (BMD) and a greater risk of falls and osteoporotic fractures. In this prospective cohort study, we examined the impact of ADT on muscle and bone strength in men initiating ADT for PCa.

Imaging Metabolically Active Fat: A Literature Review and Mechanistic Insights.

Currently, obesity is one of the leading causes death in the world. Shortly before 2000, researchers began describing metabolically active adipose tissue on cancer-surveillance F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in adult humans. This tissue generates heat through mitochondrial uncoupling and functions similar to classical brown and beige adipose tissue in mice.

Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.

Aims: Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake.